Actively Recruiting
Evaluating ELV001 as Add-on Therapy for Active Rheumatoid Arthritis in Patients Unresponsive to Methotrexate and Tumor Necrosis Factor Inhibitors A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Led by Elevara Medicines Limited · Updated on 2026-10-23
180
Participants Needed
34
Research Sites
50 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.
CONDITIONS
Brief Title
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here